Abstracts tagged "remission and rheumatoid arthritis (RA)"

Abstract Number: 838 • 2014 ACR/ARHP Annual Meeting
The Impact of Rheumatoid Arthritis Disease Activity on Cardiovascular Disease Risk: What Is the Role of the Flare?
Elena Myasoedova¹, Arun K. Chandran², Birkan İlhan³, Brittny T. Major⁴, C. John Michet III², Eric L. Matteson² and Cynthia S. Crowson⁴, ¹Internal Medicine and Rheumatology, Mayo Clinic, Rochester, MN, ²Rheumatology, Mayo Clinic, Rochester, MN, ³Department of Internal Medicine, Marmara University School of Medicine, Istanbul, Turkey, ⁴Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose Patients with rheumatoid arthritis (RA) are at increased risk of cardiovascular disease (CVD). Longitudinal studies assessing the effect of changes of RA activity on…
Abstract Number: 2926 • 2014 ACR/ARHP Annual Meeting
Calprotectin Serum Levels Reflect Residual Inflammatory Activity in Patients with Rheumatoid Arthritis and Psoriatic Arthritis on Clinical Remission or Low Disease Activity Undergoing TNF-Antagonists Therapy
Jose Inciarte-Mundo¹, M. Victoria Hernández¹, Sonia Cabrera-Villalba¹, Julio Ramirez¹, Andrea Cuervo¹, Virginia Ruiz-Esquide¹, Azucena González Navarro², Jordi Yagüe³, Juan D. Cañete¹ and Raimon Sanmarti¹, ¹Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ²Immunology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ³Immunology Department, Hospital Clinic Barcelona, Barcelona, Spain
Background/Purpose: Calprotectin is a major S100 leucocyte protein, is associated to disease activity in rheumatoid arthritis (RA) and Psoriatic Arthritis (PsA) patients. Calprotectin is a potentially…
Abstract Number: 495 • 2014 ACR/ARHP Annual Meeting
Discontinuation of Biologics in Patients with Rheumatoid Arthritis after Achieving Low-Activity Disease Status
Moeko Ochiai¹, Eri Sato¹, Eiichi Tanaka¹, Eisuke Inoue¹, Ayako Nakajima¹, Shigeki Momohara², Atsuo Taniguchi² and Hisashi Yamanaka², ¹Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ²Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: Several clinical trials have reported bio-free remission or discontinuation of biologic DMARDs; however, these findings have not been confirmed in a real-world setting. The…
Abstract Number: 2911 • 2014 ACR/ARHP Annual Meeting
Clinical Outcomes of Early RA after 7 Years – Does T2T Approach Overcome Delay of Therapy?
Tuulikki Sokka¹, Hannu Kautiainen², Tuomas Rannio³, Juha Asikainen¹ and Pekka Hannonen¹, ¹Jyvaskyla Central Hospital, Jyväskylä, Finland, ²Medcare Oy, Äänekoski, Finland, ³Kuopio University Hospital, Kuopio, Finland
Background/Purpose: Early vs. delayed referral/start of therapy within 3-4 months has been shown beneficial for outcomes in rheumatoid arthritis (RA) (Lard et al. AM J…
Abstract Number: 382 • 2014 ACR/ARHP Annual Meeting
What Is More Predictive of Achieving Remission at 12 Months: The Percentage of Baseline Improvement or the Actual Disease State Achieved at 6 Months?
Edward C. Keystone¹, Carter Thorne², Michael Starr³, Jude Rodrigues⁴, Philip Baer⁵, Regan Arendse⁶, J. Antonio Avina-Zubieta⁷, Denis Choquette⁸, Emmanouil Rampakakis⁹, John S. Sampalis⁹, May Shawi¹⁰, Francois Nantel¹⁰, Allen J Lehman¹¹ and Susan Otawa¹¹, ¹Medicine, University of Toronto, Toronto, ON, Canada, ²Southlake Regional Health Centre, Newmarket, ON, Canada, ³Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁴Clinical Research and Arthritis Centre, Windsor, ON, Canada, ⁵Private Practice, Scarborough, ON, Canada, ⁶University of Saskatchewan, Saskatoon, SK, Canada, ⁷Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁸Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: The aim of rheumatoid arthritis (RA) treatment is to optimize symptom control and, when possible, achieve sustained remission. Therefore, identification of clinical signs predicting…
Abstract Number: 2814 • 2014 ACR/ARHP Annual Meeting
Time-to-Remission, Time-to-Relapse and Disease Severity at the Time of Relapse in RA- Results from the Ontario Best Practices Research Initiative (OBRI)
Bindee Kuriya¹, Xiuying Li², Binu Jacob², Pooneh Akhavan³, Jessica Widdifield⁴, Mark Tatangelo⁵, Janet E. Pope⁶, Edward Keystone⁷ and Claire Bombardier⁸, ¹Rheumatology, University of Toronto, Toronto, ON, Canada, ²University Health Network, Toronto General Research Institute, Toronto, ON, Canada, ³Medicine, Early Rheumatoid Arthritis Program, Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, ⁴200 Elizabeth St, University of Toronto, Toronto, ON, Canada, ⁵Institute of Health Policy Management and Evaluation, University of Toronto, Toronto, ON, Canada, ⁶Medicine, Western University, London, ON, Canada, ⁷Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁸Rheumatology, Institute for Work & Health, Toronto, ON, Canada
Background/Purpose: Clinical remission in RA is the desired goal, however the ability to sustain remission and the timing and severity of relapse is not well…
Abstract Number: 365 • 2014 ACR/ARHP Annual Meeting
Differential Relative Contribution of Individual Components on DAS28 over Time: An Analysis from the Prospective, Observational, Biological Treatment Registry Across Canada
Denis Choquette¹, Dalton Sholter², Isabelle Fortin³, Michael Starr⁴, Carter Thorne⁵, Milton Baker⁶, Regan Arendse⁷, Philip Baer⁸, Michel Zummer⁹, Jude Rodrigues¹⁰, Maqbool Sheriff¹¹, Emmanouil Rampakakis¹², John S. Sampalis¹², Francois Nantel¹³, Allen J Lehman¹⁴, Susan Otawa¹⁴ and May Shawi¹³, ¹Rheumatology, Notre Dame Hospital, Montreal, QC, Canada, ²University of Alberta, Edmonton, AB, Canada, ³Centre de Rhumatologie de l'Est du Québec, Rimouski, QC, Canada, ⁴Montreal General Hospital, Montreal, QC, Canada, ⁵Southlake Regional Health Centre, Newmarket, ON, Canada, ⁶University of Victoria, Victoria, BC, Canada, ⁷University of Saskatchewan, Saskatoon, SK, Canada, ⁸Private Practice, Scarborough, ON, Canada, ⁹Université de Montréal, Montreal, QC, Canada, ¹⁰Clinical Research and Arthritis Centre, Windsor, ON, Canada, ¹¹Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ¹²JSS Medical Research, Montreal, QC, Canada, ¹³Janssen Inc., Toronto, ON, Canada, ¹⁴Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose DAS28 is an important outcome for clinical research and practice assisting with therapeutic decisions. The main contributors to DAS28 are joint tenderness and acute-phase…
Abstract Number: 2521 • 2014 ACR/ARHP Annual Meeting
Analysis on Predictors for Long-Term Clinical Efficacies of Golimumab in Patients with Rheumatoid Arthritis
Tsutomu Takeuchi¹, Yutaka Ishii², Kimie Tanaka³, Yoshifumi Ukyo⁴ and Hiroshi Sekine⁵, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Medical Affaires, Janssen Pharmaceutical K.K, Tokyo, Japan, ³Medical Affairs, Janssen Pharmaceutical K.K., Tokyo, Japan, ⁴Biostatistics Devision, Janssen Pharmaceutical K.K., Japan, Tokyo, Japan, ⁵Medical Affaires, Janssen Pharmaceutical K.K., Tokyo, Japan
Background/Purpose The GO-FORTH, phase 2/3 clinical trial was conducted to examine the efficacy and safety of Golimumab (GLM) plus MTX in Japanese patients (pts) with…
Abstract Number: 351 • 2014 ACR/ARHP Annual Meeting
Doctor, Will My Fatigue be Better If I’m in Remission? an Exploratory Analysis of 1284 Rheumatoid Arthritis (RA) Patients Indicates Fatigue Is the Only Aspect of Patient-Perceived Impact to Remain Significant in ACR/EULAR Boolean Remission
Laure Gossec^1,2,3, Bruno Fautrel^2,4, John Kirwan¹, Andra Balanescu¹, Maarten de Wit³, Ben A.C. Dijkmans¹, Matthias Englbrecht¹, Philippe Gaudin⁴, Feride Gogus¹, Turid Heiberg³, Tore Kristian Kvien¹, Emilio Martín-Mola⁵, Marco Matucci-Cerinic¹, Kati Otsa³, Adeline Ruyssen-Witrand⁴, Tuulikki Sokka-Isler¹, Martin Soubrier⁴ and Maxime Dougados^1,4, ¹RAID working group for EULAR, Zurich, Switzerland, ²Rheumatology, UPMC GRC08, Paris 06 University, Pitié Salpétrière Hospital, Paris, France, ³PsAID taskforce, EULAR, Zurich, Switzerland, ⁴COMEDRA trial group, Paris, France, ⁵Rheumatology, Hospital Universitario La Paz, Madrid, Spain
Background/Purpose Fatigue is an important issue for patients with rheumatoid arthritis (RA). The ACR/EULAR Boolean definition of remission comprises values 1/10) is a status which…
Abstract Number: 2496 • 2014 ACR/ARHP Annual Meeting
Predictors of ACR/EULAR Boolean and SDAI Remission in Patients with Established Rheumatoid Arthritis Treated with Anti-TNF: An Analysis from the Prospective, Observational, Biological Treatment Registry Across Canada
Boulos Haraoui¹, Maqbool Sheriff², Majed Khraishi³, Michael Starr⁴, John Kelsall⁵, Milton Baker⁶, Regan Arendse⁷, Sanjay Dixit⁸, William Bensen⁹, Philip Baer¹⁰, Rafat Faraawi⁸, Emmanouil Rampakakis¹¹, John S. Sampalis¹¹, Susan Otawa¹², Allen J Lehman¹², Francois Nantel¹³ and May Shawi¹³, ¹Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, ²Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ³Nexus Clinical Research, St John's, NF, Canada, ⁴Montreal General Hospital, Montreal, QC, Canada, ⁵The Mary Pack Arthritis Centre, Vancouver, BC, Canada, ⁶University of Victoria, Victoria, BC, Canada, ⁷University of Saskatchewan, Saskatoon, SK, Canada, ⁸McMaster University, Hamilton, ON, Canada, ⁹Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ¹⁰Private Practice, Scarborough, ON, Canada, ¹¹JSS Medical Research, Montreal, QC, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹³Janssen Inc., Toronto, ON, Canada
Background/Purpose Early achievement of remission is associated with improved clinical, functional and radiographic outcomes1. Recent recommendations of the Canadian Rheumatology Association dictate that treatment target…
Abstract Number: 134 • 2014 ACR/ARHP Annual Meeting
Histopathological Correlation of Ultrasound-Defined Active Synovitis in Patients with Rheumatoid Arthritis in Clinical Remission. Preliminary Results
Julio Ramirez¹, Virginia Ruiz-Esquide¹, Raquel Celis², Alicia Usategui³, Regina Faré⁴, Andrea Cuervo¹, Sonia Cabrera-Villalba⁵, Maria Victoria Hernández⁶, Jose Inciarte-Mundo¹, Jose L. Pablos⁴, Raimon Sanmarti⁷ and Juan D. Cañete⁵, ¹Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ²Arthritis Unit, Rheumatology Department, Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona and IDIBAPS, Barcelona, Spain, ³Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain, ⁴Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, ⁵Rheumatology, Hospital Clinic, Barcelona, Spain, ⁶Rheumatology, Hospital Clínic of Barcelona. IDIBAPS. University of Barcelona, Barcelona, Spain, ⁷Rheumatology, Clinic Hospital, Barcelona, Spain
Background/Purpose We recently demonstrated that 45.4% of patients with RA in clinical remission have ultrasound (US)-defined active synovitis (synovial hypertrophy (HS) grade 2 or higher…
Abstract Number: 2511 • 2014 ACR/ARHP Annual Meeting
Predictors of Discontinuation of Biologic DMARD Therapy Due to Remission in Patients with Rheumatoid Arthritis in a National Registry
Jose A Gomez-Puerta^1,2, M. Victoria Hernández¹, Fernando Sanchez-Alonso³, Kazuki Yoshida^2,4, Raimon Sanmarti¹, Daniel H Solomon², Juan J Gomez-Reino⁵ and On behalf of BIOBADASER 2.0 study group³, ¹Arthritis Unit, Department of Rheumatology, Hospital Clinic, Barcelona, Barcelona, Spain, ²Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, Boston, MA, ³Unidad de Investigación, Spanish Society of Rheumatology, Madrid, Spain, ⁴Department of Rheumatology, Kameda Medical Center, Kamogawa, Japan, Kamogawa, Japan, ⁵Hospital Clinico Universitario at the Universidad de Santiago de Compostela, Santiago, Spain
Background/Purpose: Remission is considered an achievable goal for many patients under biologic therapies. However, currently there is limited information about predictors of discontinuation of biologic…
Abstract Number: 2394 • 2014 ACR/ARHP Annual Meeting
Sustained Remission Improves Physical Function in RA Patients Treated with Tumor Necrosis Factor Inhibitor
Jon T. Einarsson¹, Meliha C. Kapetanovic² and Pierre Geborek³, ¹Dept of Clinical Sciences, Section of Rheumatology, Lund University, Lund, Sweden, ²Dept of Clinical Sciences Lund, Section of Rheumatology, Lund University, Lund, Sweden, ³Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden
Sustained Remission Improves Physical Function In RA Patients Treated with Tumor Necrosis Factor InhibitorsBackground/Purpose Remission is increasingly becoming a treatment goal in rheumatoid arthritis (RA)…
Abstract Number: 2403 • 2014 ACR/ARHP Annual Meeting
From Early Arthritis Clinic to Remission Clinic: Short-Term Outcome and Ultrasonographic-Synovitis Dynamics in Rheumatoid Arthritis Patients in DMARD-Induced SDAI-Remission during Drug-Free Follow-up
Antonio Manzo¹, Francesca Benaglio¹, Garifallia Sakellariou¹, Martina Scarabelli¹, Elisa Binda¹, Barbara Vitolo¹, Serena Bugatti¹, Roberto Caporali² and Carlomaurizio Montecucco¹, ¹Rheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico S.Matteo Foundation/University of Pavia, Pavia, Italy, ²Division of Rheumatology, Rheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico S.Matteo Foundation/University of Pavia, Pavia, Italy
Background/Purpose The introduction of DAS-driven intensive treatment strategies in early rheumatoid arthritis (RA) has considerably improved outcome and patients’ quality of life. Previous studies have…
Abstract Number: 2391 • 2014 ACR/ARHP Annual Meeting
Sustained Rheumatoid Arthritis Remission and Low Disease Activity: Analysis of 13 Years of Follow up in Clinical Practice
G. Avila¹, Arnald Alonso¹, María América López-Lasanta¹, Andrea Pluma-Sanjurjo², C. Diaz² and Sara Marsal¹, ¹Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ²Rheumatology, University Hospital Vall d'Hebron, Barcelona, Spain
Background/Purpose Biological therapies (BTs) have greatly improved the outcomes in RA patients and nowadays clinical remission (REM) and low disease activity (LDA) have become realistic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].